SCHEMBL3564975

SCHEMBL3564975

COc1ccccc1C(NC(=O)Nc1ccc(Cl)cc1)C(=O)NC1=CCC(=NN(C)C)C=C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.40
CNR1 P21554 2/20 0.40
ATM Q13315 1/20 0.40
MEN1 O00255 5/20 0.39
KMT2A Q03164 5/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
ALDH1A1 P00352 2/20 0.39
NPC1 O15118 2/20 0.39
MAPT P10636 4/20 0.37
UTS2R Q9UKP6 3/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
ROCK2 O75116 1/20 0.36
ROCK1 Q13464 1/20 0.36
NPSR1 Q6W5P4 2/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
LPAR1 Q92633 1/20 0.36
FPR2 P25090 1/20 0.36
RAB9A P51151 1/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3566489 0.90 UTS2R (0.37) LMNACNR1MEN1KMT2ASMN1; SMN2
SCHEMBL3564411 0.89 CNR1 (0.36) LMNACNR1MEN1KMT2ASMN1; SMN2
SCHEMBL3560347 0.89 RAB9A (0.38) LMNACNR1MEN1KMT2ASMN1; SMN2
SCHEMBL3573284 0.88 CNR1 (0.36) LMNACNR1MEN1KMT2ASMN1; SMN2
SCHEMBL3564560 0.88 UTS2R (0.36) LMNACNR1MEN1KMT2ASMN1; SMN2
SCHEMBL3559267 0.87 FPR2 (0.42) CNR1MEN1KMT2ASMN1; SMN2MAPT
SCHEMBL3570075 0.87 MAPT (0.38) LMNACNR1ATMMEN1KMT2A
SCHEMBL3567171 0.82 HTT (0.42) LMNACNR1MEN1KMT2ASMN1; SMN2
SCHEMBL3570284 0.79 FPR2 (0.43) LMNACNR1MEN1KMT2ASMN1; SMN2
SCHEMBL3567078 0.79 MAPT (0.43) LMNACNR1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US claimed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US claimed
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160821-A1 Ureas as factor Xa inhibitors TFPI, F12, F11 LMNA 938/4885CNR1 1500/4885ATM 2641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.